Is LifeVantage Corp. overvalued or undervalued?

As of 17 October 2025, the valuation grade for LifeVantage Corp. moved from attractive to very attractive, indicating a strong improvement in its valuation outlook. The company appears undervalued, supported by a P/E ratio of 17, a PEG ratio of 0.11, and an EV to EBITDA ratio of 8.48, all of which suggest that the stock is trading at a discount compared to its growth potential. In comparison to peers, Chromadex Corp. has a significantly higher P/E ratio of 39.82, while USANA Health Sciences, Inc. is considered expensive with a P/E of 16.23.
Despite recent challenges reflected in the stock's performance, with a year-to-date return of -49.74% compared to the S&P 500's 13.30%, the long-term outlook remains promising, as evidenced by a 3-year return of 130.63% against the benchmark's 81.19%. This divergence in performance highlights the potential for recovery and growth in LifeVantage Corp.